PCSK9 inhibitors:Monoclonal antibodies for the treatment of hypercholesterolemia

Drugs of Today

Volumn 52, Issue 3, 2016, Pages 183-192

  Paton, D M ^a  

^a Nanaimo ^*  (Canada)

Author keywords

Alirocumab; Evolocumab; Familial hypercholesterolemia; Hypercholesterolemia; PCSK9; Proprotein convertase subtilisin kexin type 9; Statin intolerance

Indexed keywords

ALIROCUMAB; ANTILIPEMIC AGENT; EVOLOCUMAB; LIPOPROTEIN; MONOCLONAL ANTIBODY; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE PAIN; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; REVIEW; RHINOPHARYNGITIS; ANTAGONISTS AND INHIBITORS; BLOOD;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 85047288830     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2016.52.3.2440527     Document Type: Review

References (31)

1. Norata, G.D., Tibolla, G., Catapano, A.L. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 2014, 54: 273-93.
2. Abifadel, M., Rabès, J.P., Devillers, M., Munnich, A., Erlich, D., Junien, C., Varret, M., Boileau, C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009, 30(4): 520-9.
3. Davignon, J., Dubuc, G., Seidah, N.G. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep 2010, 12(5): 308-15.
4. Piper, D.E., Jackson, S., Liu, Q. et al. The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol. Structure 2007, 15(5): 545-52.
5. Stein, E.A., Raal, F. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 2014, 65: 417-31.
6. Schulz, R., Schlüter, K-D., Laufs, U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol 2015, 110(2): 4.
7. Bergeron, N., Phan, B.A.P., Ding, Y., Fong, A., Krauss, R.M. Proprotein convertase subtilisin/kexin type 9 inhibition: A new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 2015, 132(17): 1648-66.
8. Markham, A. Alirocumab: First global approval. Drugs 2015, 75(14): 1699-705.
9. Markham, A. Evolocumab: First global approval. Drugs 2015, 75(14): 1567-73.
10. Keating, G.B. Evolocumab: A review in hyperlipidemia. Am J Cardiovasc Drugs 2016, 16(1): 67-78.
11. Lunven, C., Paehler, T., Poitiers, F., Brunet, A., Rey, J., Hanotin, C., Sasiela, W.J. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther 2014, 32(6): 297-301.
12. Stein, E.A., Mellis, S., Yancopoulos, G.D. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366(12): 1108-18.
13. Gibbs, J.P., Grover, A., Emery, M.G., Dodds, M., Somaratne, R., Wasserman, S.M. Impact of target-mediated elimination on evolocumab dose and regimen. 83rd Eur Atheroscler Soc (EAS) Congr (March 22-25, Glasgow) 2015, Abst 422.
14. Stein, E. A., Koren, M., Honarpour, N. et al. Clinical equivalence of evolocumab 140 mg every two weeks and 420 mg monthly dosing regimens: A pooled analysis of 3146 patients in phase 3 studies. 64th Annu Sci Sess Am Coll Cardiol (ACC) (March 14-16, San Diego) 2015, Abst 1107-103.
15. Stein, E.A., Giugliano, R.P., Koren, M.J. et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: Pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014, 35(33): 2249-59.
16. Navarese, E.P., Kolodziejczak, M., Schulze, V. et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis. Ann Intern Med 2015, 163(1): 40-51.
17. Zhang, X-L., Zhu, Q-Q., Zhu, L., Chen, J.Z., Chen, Q.H., Li, G.N., Xie, J., Kang, L.N., Xu, B. Safety and efficacy of anti- PCSK9 antibodies: A meta-analysis of 25 randomized, controlled trials. BMC Med 2015, 13: 123-140.
18. Li, C., Lin, L., Zhang, W., Zhou, L., Wang, H., Luo, X., Luo, H., Cai, Y., Zeng, C. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: A meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015, 4(6): e001937.
19. Lipinski, M.J., Benedetto, U., Escarcega, R.O., Biondi-Zoccai, G., Lhermusier, T., Baker, N.C., Torquson, R., Brewer, H.B. Jr., Waksman, R. The impact of proprotein convertase subtilisinkexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis. Eur Heart J 2016, 37(6): 536-45.
20. Raal, F.J., Stein, E.A., Dufour, R. et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A andomized, double-blind, placebo-controlled trial. Lancet 2015, 385(9965): 331-40.
21. Raal, F.J., Honarpour, N., Blom, D.J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A andomized, double-blind, placebo-controlled trial. Lancet 2015, 385(9965): 341-50.
22. Roth, E.M., McKenney, J.M., Hanotin, C., Asset, G., Stein, E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012, 367(20): 1891-900.
23. Sullivan, D., Olsson, A.G., Scott, R., Kim, J.B., Xue, A., Gebski, V., Wasserman, S.M., Stein, E.A. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA 2012, 308(23): 2497-506.
24. Kurt, B., Soufi, M., Sattler, A., Schaefer, J.R. Lipoprotein(a) - Clinical aspects and future challenges. Clin Res Cardiol Suppl 2015, 10: 26-32.
25. Mbikay, M., Sirois, F., Mayne, J., Wang, G.S., Chen, A., Dewpura, T., Prat, A., Seidah, N.G., Chretien, M., Scott, F.W. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010, 584: 701-6.
26. Temel, R.E., Brown, J.M. A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion. Trends Pharmacol Sci 2015, 36(7): 440-51.
27. Hassan, M. OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events. Glob Cardiol Sci Pract 2015, 2015(2): 20.
28. Everett, B.M., Smith, R.J., Hiatt, W.R. Reducing LDL with PCSK9 inhibitors - The clinical benefit of lipid drugs. N Engl J Med 2015, 373(17): 1588-91.
29. Schulman, K.A., Balu, S., Reed, S.D. Speciality pharmaceuticals for hyperlipidemia - Impact on insurance premiums. N Engl J Med 2015, 373(17): 1591-3.
30. Newman, C.B., Tobert, J.A. Statin intolerance: Reconciling clinical trials and clinical experience. JAMA 2015, 313(10): 1011-2.
31. Jin, J. JAMA patient page. PCSK9 inhibitors for treating high cholesterol. JAMA 2015, 314(21): 2320.